2022 Fiscal Year Final Research Report
Innovation of novel therapeutics against diabetic nephropathy
| Project/Area Number |
21K19692
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 59:Sports sciences, physical education, health sciences, and related fields
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岩渕 好治 東北大学, 薬学研究科, 教授 (20211766)
横山 敦 東北大学, 医学系研究科, 准教授 (20572332)
|
|---|
| Project Period (FY) |
2021-07-09 – 2023-03-31
|
| Keywords | 糖尿病性腎症 / TXNIP / ChREBP / 酸化ストレス / RNAシークエンス |
|---|
| Outline of Final Research Achievements |
We have previously identified D-532 by the high-throughput screening using the chemical library. D-532 protected kidney function in both type 1 and type 2 diabetic mice that express diabetic nephropathy (DN). In the present study, we have identified that TXNIP gene, which is a key molecule for the high-glucose induced ROS, is the target gene of D-532 by RNA sequencing using RNA extracted from kidney cortex of type 1 DN mice. D-532 may therefore be a potential therapeutic against DN in the near future.
|
| Free Research Field |
内分泌・代謝学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究課題により、我々が見出した新規化合物D-532の標的遺伝子が、高血糖誘導性の酸化ストレス亢進に関与するTXNIPである可能性が推定された。今後、D-532を基盤とした新規DN治療薬・治療法の開発を進めるが、本研究の遂行は国民の健康福利・医療経済に大きく貢献できるものを期待される。
|
